Hims Daily (Feb 12, 2025)
Despite CPI reading, HIMS closes (yet again) at new all-time high 🔥
Stock Price: $46.38
Today: +$2.80 (+6.42%)
Past month: +$20.48 (+79.07%)
Past year: +$36.90 (+389.24%)
🚨 Get exclusive access to our Q4 earnings prediction and Q1 guidance projections — released next week. Subscribe now for access
What’s Happening
Shares jumped 6.42% today to close at $46.38, a brand new all-time high close. The stock opened at $43.00 and dipped as low as $42.80 before rallying throughout late-day trading.
Trading sentiment was fueled by high institutional ownership — now 75% — and a 33% short interest, prompting further discussions about a potential short squeeze. Traders noted that large funds continue to accumulate shares, tightening the float even further.
HIMS Super Bowl ad had ~8x as much engagement as the average Super Bowl ad, according to advertising data analytics company EDO.
HIMS’ ad was the #5 ad OVERALL, and the #1 ad in the pharma category, based on EDO's "Engagement Index". Very cool to see.
Many investors pointed to expanded product offerings—like weight loss and potential future categories (e.g. menopause, TRT)—as key long-term growth drivers. Bears, however, voiced concerns about the FDA eventually ending the shortage designation for GLP-1 compounding, which could reduce revenue.
Catalysts
T-12 days until Q4 earnings
FDA decisions on semaglutide + tirzepatide
Greenland / Trump tariffs
HIMS to appear at Morgan Stanley’s Technology, Media & Telecom Conference in March
S&P MidCap 400 potential inclusion on March 21?
Top Tweets
The HIMS thesis in 20 bullets:
